Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies (NASDAQ: BSGM) has announced a partnership with the Cleveland Clinic to explore expanded clinical applications for its PURE EP™ System. This research agreement aims to enhance digital signal processing in electrophysiology, particularly in cardiac ablation procedures. Cleveland Clinic's expertise will help identify new workflows and improve arrhythmia treatment methods. The PURE EP™ System, recently rated superior to conventional systems in a blinded study, is gaining traction in major healthcare systems amid a growing electrophysiology market projected to reach $16 billion by 2028.
BioSig Technologies (NASDAQ: BSGM) will present its PURE EP™ System at the 17th Edition Venice Arrhythmias 2022 Congress from October 13-15, 2022. This event marks the first introduction of the advanced digital signal processing technology to the European electrophysiology market. The PURE EP™ System, designed to enhance intracardiac signal visualization, showcases features like signal processing automation and comprehensive procedural analysis via the ACCUVIZ™ Module. The global electrophysiology market is projected to reach $16 billion by 2028 with an 11.2% growth rate.
BioSig Technologies announces that the PURE EP™ System has been acquired by Methodist Hospital in San Antonio. This acquisition signals continued expansion for BioSig as it enhances cardiac care by integrating with current workflows and providing superior signal visualization, crucial for complex cardiac ablation procedures. The PURE EP™ System has been rated highly by electrophysiologists, with 93.6% of signal samples being equivalent or superior to conventional systems. The global electrophysiology market is projected to grow 11.2% annually, reaching $16B by 2028.
BioSig Technologies (BSGM) has announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module, enhancing its signal processing technology.
This update features a High Frequency Algorithm for improved cardiac data visualization, along with Automatic Tachycardia Characterization and TRUSOURCE Analysis. The software aims to optimize workflows for electrophysiologists.
BioSig will present this innovation at the Cleveland Clinic Global EP Summit on September 23-24, 2022.
BioSig Technologies (NASDAQ: BSGM) recently announced significant enhancements to its commercial strategy, focusing on expanding its sales and marketing teams. The company has doubled its sales force and plans to triple it by Q4 2022, appointing new National Account Executives to drive the adoption of its innovative PURE EP™ System. Additionally, a newly strengthened marketing team will implement a comprehensive strategy to boost brand equity and market presence. Key clinical data demonstrating a 75% improvement in signal quality from the PURE EP™ System has been published, further validating its competitive edge.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced the installation of a second PURE EP™ System at the Cleveland Clinic, enhancing access to its signal processing technology. The additional unit supports the clinical evaluation of PURE EP™ across both Main and Fairview campuses of the Heart, Vascular & Thoracic Institute. BioSig's strategy aims to expand physician engagement with its technology, which has gained traction among electrophysiology labs in the Midwest. The company also plans to participate in the Cleveland Clinic Global EP Summit 2022, showcasing advancements in electrophysiology care.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced its participation in the Kansas City Heart Rhythm Symposium on August 20-21, 2022. The company's PURE EP™ System, aimed at enhancing cardiac electrophysiology procedures, will be highlighted in a presentation by Dr. Hicham El Masry. The event will also feature product demonstrations and updates on the clinical pipeline. Additionally, a physician-led research protocol studying the PURE EP™ System during RF ablation is underway at the Kansas City Heart Rhythm Institute, focusing on participants with paroxysmal atrial fibrillation.
BioSig Technologies, Inc. (NASDAQ: BSGM) reports a boost in its sales pipeline following the recent commercial launch of the PURE EP™ System. The company is seeing increased interest from medical centers, including new agreements with the Cleveland Clinic and Kansas City Heart Rhythm Institute. BioSig has streamlined evaluation agreements to 60 days and introduced a leasing program, aiming for faster adoption of its technology. CEO Kenneth Londoner anticipates continued growth in commercial activity driven by rising demand for minimally invasive procedures.
BioSig Technologies (NASDAQ: BSGM) announced a new research study led by Dr. Dhanunjaya DJ Lakkireddy at the Kansas City Heart Rhythm Institute. This study will examine the efficacy of the PURE EP™ System during Radiofrequency ablation in patients with paroxysmal atrial fibrillation, involving 30 participants. Positive outcomes could reduce procedural costs and duration. Additionally, Overland Park Regional Medical Center signed a national purchasing agreement to acquire the PURE EP™ System, marking a significant commercial milestone for BioSig.
BioSig Technologies (NASDAQ: BSGM) announces a pivotal agreement with Kansas City Heart Institute at Overland Park Regional Medical Center, marking its first leasing agreement under a new program. The purchase agreement for the PURE EP™ System signifies the technology's commercial adoption and establishes a national master agreement with a major U.S. healthcare system. Executives believe this agreement is crucial for enhancing heart rhythm procedures and improving patient outcomes, highlighting the importance of physician feedback in product evolution.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
